There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C
Goals The goal of this study was to examine the effect of a st and ardized silybin and soy phosphatidylcholine complex ( IdB 1016 ) on serum markers of iron status . Background Milk thistle and its components are widely used as an alternative therapy for liver disease because of purported antioxidant , anti-inflammatory , and iron chelating properties . Study Thirty-seven patients with chronic hepatitis C and Batts-Ludwig fibrosis stage II , III , or IV were r and omized to 1 of 3 doses of IdB 1016 for 12 weeks . Serum ferritin , serum iron , total iron binding capacity , and transferrin-iron saturation were measured at baseline , during treatment , and 4 weeks thereafter . Wilcoxon signed rank tests were used to compare baseline and posttreatment values . Results There was a significant decrease in serum ferritin from baseline to end of treatment ( mean , 244 vs. 215 μg/L ; median , 178 vs. 148 μg/L ; P=0.0005 ) ; 78 % of subjects had a decrease in serum ferritin level . There was no significant change in serum iron or transferrin-iron saturation . Multivariate logistic regression analysis in a model that included dose , age , sex , HFE genotype , history of alcohol use , and elevated baseline ferritin levels demonstrated that stage III or IV fibrosis was independently associated with decreased posttreatment serum ferritin level . Conclusions Treatment with IdB 1016 is associated with reduced body iron stores , especially among patients with advanced fibrosis stage
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .